Described herein are treatment methods involving the administration of nicotinamide, which has been discovered to stabilize the normal phenotype of retinal pigment epithelial cells and to prevent retinal pigment epithelial cell proliferation. Diseases and disorders that can be treated according to the methods disclosed herein include, e.g., macular pucker, proliferative vitreoretinopathy, preretinal fibrosis, vitreomacular traction, tractional retinal detachment, and phthsis bulbi, cystoid macular edema (CME) arising from intraocular inflammation due to uveitis, vasculitis, trauma, surgery, and collagen vascular disease (e.g., Behcets disease or sarcoidosis), and age related macular degeneration.
